Cancer remains one of the most difficult diseases to treat, requiring continuous research into innovative therapeutic strategies. Conventional treatments such as chemotherapy and radiotherapy are effective to a certain extent but often have significant side effects and carry the risk of resistance. In recent years, the concept of dual-acting therapeutics has attracted considerable attention, particularly the combination of DNA alkylating agents and antimicrobial peptides. DNA alkylation, a well-known mechanism in cancer therapy, involves the attachment of alkyl groups to DNA, leading to DNA damage and subsequent cell death. Antimicrobial peptides, on the other hand, have been shown to be effective anticancer agents due to their ability to selectively disrupt cancer cell membranes and modulate immune responses. This review aims to explore the synergistic potential of these two therapeutic modalities. It examines their mechanisms of action, current research findings, and the promise they offer to improve the efficacy and specificity of cancer treatments. By combining the cytotoxic power of DNA alkylation with the unique properties of antimicrobial peptides, dual-action therapeutics may offer a new and more effective approach to fighting cancer.
癌症仍是目前最难治疗的疾病之一，需要持续探索创新性治疗策略。化疗和放疗等传统疗法虽具有一定疗效，但常伴随显著副作用及耐药风险。近年来，双效治疗理念备受关注，其中DNA烷化剂与抗菌肽的联合应用尤为突出。DNA烷化作为成熟的癌症治疗机制，通过烷基与DNA结合引发DNA损伤，最终导致细胞死亡。而抗菌肽因其能选择性破坏癌细胞膜并调节免疫应答，已被证实具有抗癌潜力。本文旨在探讨这两种治疗模式的协同效应，系统分析其作用机制、现有研究成果，以及其在提升癌症治疗效能与特异性方面的应用前景。通过整合DNA烷化剂的细胞毒性与抗菌肽的独特性质，双效治疗策略或将为抗击癌症提供全新且更有效的途径。
Dual-Action Therapeutics: DNA Alkylation and Antimicrobial Peptides for Cancer Therapy
肿瘤(癌症)患者之家